CERo Therapeutics doses sixth patient in phase 1 cancer trial

April 14, 2026 8:15 AM

CERo Therapeutics Holdings Inc. (OTCQB: CERO) dosed the third patient in the second cohort of its Phase 1 CER-1236 clinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found